Related Experiment Videos
[Type 2 diabetes mellitus and coronary heart disease]
M Brändle1, F W Amann, F Salomon
1Abteilung für Endokrinologie/Diabetologie, Universitätsspital Zürich. ndobraem@usz.unizh.ch
Insights
Type 2 diabetes significantly increases risks for coronary artery disease and heart attack mortality. Prompt treatment, including insulin-glucose infusion and standard medications, improves outcomes for diabetic patients with acute myocardial infarction.
Area of Science:
- Cardiology
- Endocrinology
- Diabetology
Context:
- Type 2 diabetes mellitus is a major risk factor for cardiovascular disease.
- Diabetic patients face a substantially higher risk of myocardial infarction and related mortality compared to non-diabetics.
Purpose:
- To outline optimal management strategies for diabetic patients experiencing acute myocardial infarction.
- To emphasize the benefits of timely interventions and secondary prevention in this high-risk population.
Summary:
- Diabetic patients with acute myocardial infarction require rapid thrombolytic therapy, similar to non-diabetics, with diabetic retinopathy not being a contraindication.
- Management should include aspirin, beta-blockers, and ACE-inhibitors.
- Insulin-glucose infusion therapy during acute myocardial infarction, particularly for those with hyperglycemia (> 11 mmol/l), significantly reduces 12-month mortality by approximately 30% and improves long-term prognosis.
Impact:
- Highlights the critical need for aggressive and evidence-based treatment for diabetic patients with acute myocardial infarction.
- Reinforces the efficacy of established secondary prevention medications (aspirin, statins, beta-blockers, ACE-inhibitors) in diabetic individuals.
- Demonstrates the life-saving potential of insulin-glucose infusion therapy in improving survival rates and long-term outcomes for diabetic patients post-myocardial infarction.
Abstract:
Coronary artery disease is the most common cause of morbidity and mortality in subjects with type 2 diabetes mellitus. The risk of coronary artery disease, myocardial infarction and mortality from myocardial infarction is markedly increased in type 2 diabetic patients compared with non-diabetics. Diabetic patients with acute myocardial infarction should receive thrombolytic therapy as rapidly as possible and for the same indications as non-diabetics. Diabetic retinopathy is not a contraindication to treatment. The management of diabetic patients should also include medication with aspirin, beta-blockers and ACE-inhibitors. An insulin-glucose infusion during acute myocardial infarction, followed by insulin injections subcutaneously, reduces mortality by about 30% after 12 months and improves long-term prognosis. Thus, insulin-glucose infusion in diabetic patients with acute myocardial infarction, especially in those with a high blood glucose level (> 11 mmol/l), seems advisable. Diabetic patients benefit from secondary prevention by drug therapy (aspirin, lipid lowering with statins, beta-blockers and ACE-inhibitors) to the same extent as, or more than, non-diabetic patients.